Clinical Trials Browser

Recruiting × orelabrutinib × 90 days × Clear all

NCT07448324 2026-03-04

Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL

Phase 2 Recruiting

Lymphoma, B-Cell, Marginal Zone

NCT07355699 2026-01-21

Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone Lymphoma

Phase 4 Recruiting

Lymphoma, B-Cell, Marginal Zone